2000 Volume 48 Issue 4 Pages 559-562
In the process development of lovastatin using Aspergillus terreus DRCC 152 in solid state fermentation, we have isolated a new butyrolactone-IV (3) along with the previously reported butyrolactone-I (1) and butyrolactone-II (2) produced under submerged conditions. The structure of compound 3 has been characterized as 3-hydroxy-5-{2-(1-hydroxy-1-methylethyl)-2-(R)-2, 3-dihydro-benzo[b]furan-5 ylmethyl}-4-(4-hydroxyphenyl)-5-methoxycarbonyl-(5R)-2, 5-dihydro-(5R)-2, 5-dihydro-2-furanone on the basis of spectroscopic studies. The absolute stereochemistry has been determined by single crystal X-ray diffraction studies. The cytotoxic and antibacterial activities of these compounds were determined.
